The present invention relates to: a compound selected from the group consisting of a tricyclic compound having the structure of formula I, a pharmaceutically acceptable salt, an isomer, a solvate and a precursor thereof; and a use thereof. The compound effectively controls GPR40, and thus, can be effectively used for the prophylaxis or treatment of diseases associated with GPR40, for example, diabetes and many other diseases.

In a non-limiting embodiment, there is provided a compound of formula (I), which may permit for a method or use in treating or preventing a cancer, such as pancreatic cancer or leukemia. In one embodiment, there is also provide a method of preparing a compound of formula (Ia), the method including conducting a cyclization reaction of a compound of formula (III) to obtain a compound of formula (IV), wherein conducting the cyclization reaction comprises conducting a Michael reaction in the presence of a Lewis acid. ##STR00001##

A novel compound is disclosed, which comprises: a 7-membered ring segment, which is formed by a cis-stilbene segment and a bridge atom with four bonds; and a fluorene segment connecting to the bridge atom with a double bond. In addition, an organic electronic device is also disclosed, and an organic layer therein comprises the novel compound of the present invention.

A novel compound is disclosed, which comprises: a 7-membered ring segment, which is formed by a cis-stilbene segment and a bridge atom with four bonds; and an acridine segment connecting to the bridge atom of the 7-membered ring segment. In addition, an organic electronic device is also disclosed, and an organic layer therein comprises the novel compound of the present invention.

The present invention provides a series of spirally configured cis-stilbene/fluorene hybrid compounds and an optoelectronic device comprising the same. The compound comprises a seven-membered ring portion. The seven-membered ring portion is composed of a cis-stilbene fragment, and a tetrahedral coordination bridging atom fragment, wherein the cis-stilbene fragment has at least one substituent, the substituent is independently a substituted or unsubstituted triazine group, pyrimidine group or phenyl group. The compounds have glass transition temperatures ranged from 156 C. to 202 C., decomposition temperatures ranged from 419 C. to 509 C., reversible electron transport property, and balanced charges motilities. In addition, a variety of experimental data have proved that these spirally configured cis-stilbene/fluorene hybrid materials can indeed be used as a hole-blocking type electron-transporter for phosphorescent OLEDs.

The present invention provides a series of diphenylimidazole-fused, spirally configured cis-stilbene/fluorene hybrid compounds and an optoelectronic device comprising the same. The diphenylimidazole-fused, spirally configured cis-stilbene/fluorene hybrid compound bearing cyanoaryl and cyanoheteroaryl substituents, and have glass transition temperatures ranged from 154 C. to 194 C., decomposition temperatures ranged from 426 C. to 443 C., reversible electron transport property, and balanced charges motilities. In addition, a variety of experimental data have proved that these diphenylimidazole-fused, spirally configured cis-stilbene/fluorene hybrid materials can indeed be used as a hole-blocking type electron-transporter for phosphorescent OLEDs.

It belongs to the field of medicinal chemistry, in particular discloses anti-inflammatory and analgesic compounds and use thereof, the compounds of the present invention are compounds, isomers or pharmaceutically acceptable salts as shown in formula (I) or formula (II); the compounds have significant curative effect on gouty arthritis in rats, and have excellent anti-inflammatory factor effect; therefore, the compounds have potential application prospects in anti-inflammatory and analgesic drugs, especially in anti-acute gouty arthritis drugs, anti-rheumatoid arthritis drugs, drugs to reduce inflammatory factors, drugs to treat inflammatory storm or coronavirus pneumonia.

Tricyclic chemical modulators of protein phosphatase 2A are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazine and dibenzoazepine compounds and similar genera:

##STR00001##

This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I)

##STR00001##

wherein

##STR00002##

Q, J, L and Z are as defined in the specification.

The present disclosure comprises hydrophilic linker compounds of Formula 1:

##STR00001## and describes methods for their use in liquid phase synthesis. In Formula 1, m is 0 to 20, n is 1 to 50, and Z is a linker compound as described herein.